NewEdge Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

NewEdge Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.47K	Sell	3,500 -2,623	-43%	-$6.42K	﹤0.01%	3643
2026 Q1	$13K	Buy	+6,123	New	+$14.6K	﹤0.01%	3324
2025 Q4	–	Sell	-17	Closed	-$64	–	4228
2025 Q3	$64	Hold	17	–	–	﹤0.01%	4048
2025 Q2	$42	Hold	17	–	–	﹤0.01%	3937
2025 Q1	$26	Hold	17	–	–	﹤0.01%	3880
2024 Q4	$36	Hold	17	–	–	﹤0.01%	3829
2024 Q3	$74	Hold	17	–	–	﹤0.01%	3731
2024 Q2	$79	Hold	17	–	–	﹤0.01%	3697
2024 Q1	$86	Hold	17	–	–	﹤0.01%	3708
2023 Q4	$48	Hold	17	–	–	﹤0.01%	3670
2023 Q3	$49	Hold	17	–	–	﹤0.01%	3401
2023 Q2	$86	Hold	17	–	–	﹤0.01%	3426
2023 Q1	$32	Sell	17 -96	-85%	-$221	﹤0.01%	3373
2022 Q4	$173	Buy	+113	New	+$204	﹤0.01%	3315

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

NewEdge Advisors's BDTX Position: Q2 2026 in Review

NewEdge Advisors reduced its Black Diamond Therapeutics (BDTX) stake by 43% in Q2 2026, selling an estimated $6.42K and leaving 3,500 shares worth $6.47K. The position accounts for ﹤0.01% of the portfolio, ranked #3643.

NewEdge Advisors first reported a position in BDTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $13K in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

NewEdge Advisors held 3,500 shares of Black Diamond Therapeutics worth $6.47K as of Q2 2026.
NewEdge Advisors sold 2,623 Black Diamond Therapeutics shares in Q2 2026, an estimated $6.42K.
Black Diamond Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3643 holding.
NewEdge Advisors first reported a position in Black Diamond Therapeutics in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's Black Diamond Therapeutics position peaked at $13K in Q1 2026.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.